MCID: LPS004
MIFTS: 69

Lupus Erythematosus

Categories: Rare diseases, Skin diseases, Bone diseases, Genetic diseases, Nephrological diseases, Immune diseases

Aliases & Classifications for Lupus Erythematosus

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 72 49 51 14 69
Lupus 12 49 40 3
Subacute Cutaneous Lupus 49 69
Disseminated Lupus Erythematosus 49
Lupus Erythematosus, Systemic 69
Systemic Lupus Erythematosus 49
Lupus Erythematosus, Discoid 69
Lupus Vulgaris 69
Discoid Lupus 49
Sle 49

Classifications:



External Ids:

Disease Ontology 12 DOID:8857
ICD10 32 L93 L93.0
ICD9CM 34 695.4
NCIt 46 C27153
SNOMED-CT 64 200936003 200944003

Summaries for Lupus Erythematosus

MedlinePlus : 40 What is lupus? Lupus is an autoimmune disease. This means that your immune system attacks healthy cells and tissues by mistake. This can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. There are several kinds of lupus Systemic lupus erythematosus (SLE) is the most common type. It can be mild or severe, and can affect many parts of the body. Discoid lupus causes a red rash that doesn't go away Subacute cutaneous lupus causes sores after being out in the sun Drug-induced lupus is caused by certain medicines. It usually goes away when you stop taking the medicine. Neonatal lupus, which is rare, affects newborns. It is probably caused by certain antibodies from the mother. Who gets lupus? Anyone can get lupus, but women are most at risk. Lupus is two to three times more common in African American women than in Caucasian women. It's also more common in Hispanic, Asian, and Native American women. African American and Hispanic women are more likely to have severe forms of lupus. What causes lupus? The cause of lupus is not known. What are the symptoms of lupus? Lupus can have many symptoms, and they differ from person to person. Some of the more common ones are Pain or swelling in joints Muscle pain Fever with no known cause Red rashes, most often on the face (also called the "butterfly rash") Chest pain when taking a deep breath Hair loss Pale or purple fingers or toes Sensitivity to the sun Swelling in legs or around eyes Mouth ulcers Swollen glands Feeling very tired Symptoms may come and go. When you are having symptoms, it is called a flare. Flares can range from mild to severe. New symptoms may appear at any time. How do I know if I have lupus? There is no single test to diagnose lupus, and it's often mistaken for other diseases. So it may take months or years for a doctor to diagnose it. Your doctor may use many tools to make a diagnosis: Medical history Complete exam Blood tests Skin biopsy (looking at skin samples under a microscope) Kidney biopsy (looking at tissue from your kidney under a microscope) What are the treatments for lupus? There is no cure for lupus, but medicines and lifestyle changes can help control it. People with lupus often need to see different doctors. You will have a primary care doctor and a rheumatologist (a doctor who specializes in the diseases of joints and muscles). Which other specialists you see depends on how lupus affects your body. For example, if lupus damages your heart or blood vessels, you would see a cardiologist. Your primary care doctor should coordinate care between your different health care providers and treat other problems as they come up. Your doctor will develop a treatment plan to fit your needs. You and your doctor should review the plan often to be sure it is working. You should report new symptoms to your doctor right away so that your treatment plan can be changed if needed. The goals of the treatment plan are to Prevent flares Treat flares when they occur Reduce organ damage and other problems Treatments may include drugs to Reduce swelling and pain Prevent or reduce flares Help the immune system Reduce or prevent damage to joints Balance the hormones Besides taking medicines for lupus, you may need to take medicines for problems that are related to lupus such as high cholesterol, high blood pressure, or infection. Alternative treatments are those that are not part of standard treatment. At this time, no research shows that alternative medicine can treat lupus. Some alternative or complementary approaches may help you cope or reduce some of the stress associated with living with a chronic illness. You should talk to your doctor before trying any alternative treatments. How can I cope with lupus? It is important to take an active role in your treatment. It helps to learn more about lupus - being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe. It is also important to find ways to cope with the stress of having lupus. Exercising and finding ways to relax may make it easier for you to cope. A good support system can also help. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus 16 and neonatal lupus erythematosus, and has symptoms including seizures, pruritus and heliotrope rash. An important gene associated with Lupus Erythematosus is ENG (Endoglin), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Simvastatin and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and b cells, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 49 Lupus is an autoimmune disease that can affect almost every organ in the body. Symptoms of lupus can range from very mild to life-threatening. There are three main types of lupus; systemic lupus erythematosus, discoid lupus, and drug-induced lupus. Symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. Genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors. Studies suggest that a number of different genes may be involved in determining a person’s likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. Lupus is more common in young women. The treatment of lupus depends on the severity of the condition and what parts of the body are affected. Treatment may include acetaminophen, ibuprofen, antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as BLyS-specific inhibitors (Belimumab). Last updated: 8/9/2017

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

Wikipedia : 72 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 991)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 34.8 C1QA C4A DNASE1L3
2 neonatal lupus erythematosus 34.6 C4A TRIM21
3 cutaneous lupus erythematosus 34.3 TREX1 TRIM21 TROVE2
4 pediatric systemic lupus erythematosus 34.3 C4A C4B PTPN22 STAT4
5 systemic lupus erythematosus 1 34.3 ENG TLR5 TREX1
6 vitiligo-associated multiple autoimmune disease susceptibility 1 33.8 C4B CTLA4 PTPN22
7 c1q deficiency 33.2 C1QA C1QB C1QC
8 sjogren syndrome 32.2 SSB TNFSF4 TRIM21 TROVE2
9 systemic lupus erythematosus 31.7 BANK1 C1QA C1QB C1QC C4A C4B
10 glomerulonephritis 31.1 C1QB C1QC C4A C4B
11 autoimmune disease 30.9 CTLA4 FCGR2B PDCD1 PTPN22 STAT4
12 heart block, congenital 30.5 TRIM21 TROVE2
13 wegener granulomatosis 30.5 CTLA4 PTPN22 STAT4
14 lupus erythematosus tumidus 12.7
15 subacute cutaneous lupus erythematosus 12.6
16 lupus erythematosus panniculitis 12.6
17 discoid lupus erythematosus 12.6
18 drug-induced lupus erythematosus 12.6
19 systemic lupus erythematosus 2 12.5
20 systemic lupus erythematosus 9 12.4
21 systemic lupus erythematosus 10 12.4
22 systemic lupus erythematosus 6 12.4
23 systemic lupus erythematosus 11 12.3
24 systemic lupus erythematosus with hemolytic anemia 1 12.3
25 chilblain lupus 1 12.3
26 systemic lupus erythematosus 3 12.3
27 systemic lupus erythematosus with nephritis 1 12.3
28 systemic lupus erythematosus with nephritis 2 12.3
29 systemic lupus erythematosus with nephritis 3 12.3
30 systemic lupus erythematosus 4 12.3
31 systemic lupus erythematosus 5 12.3
32 systemic lupus erythematosus 12 12.3
33 neonatal systemic lupus erythematosus 12.3
34 hypertrophic or verrucous lupus erythematosus 12.2
35 systemic lupus erythematosus 15 12.1
36 systemic lupus erythematosus 7 12.1
37 systemic lupus erythematosus 8 12.1
38 systemic lupus erythematosus 13 12.1
39 systemic lupus erythematosus 14 12.1
40 discoid lupus erythematosus of eyelid 12.0
41 mixed connective tissue disease 11.6
42 hypogonadotropic hypogonadism 11.4
43 pure red-cell aplasia 11.4
44 macrophage activation syndrome 11.4
45 epidermolysis bullosa acquisita 11.4
46 retinal vasculitis 11.4
47 pemphigus erythematosus 11.4
48 complement component 2 deficiency 11.4
49 renal tubular acidosis, distal 11.4
50 undifferentiated connective tissue disease 11.3

Graphical network of the top 20 diseases related to Lupus Erythematosus:



Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus

UMLS symptoms related to Lupus Erythematosus:


seizures, pruritus, heliotrope rash, lupus-like rash, exanthema

MGI Mouse Phenotypes related to Lupus Erythematosus:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 TROVE2 TLR5 TNFSF4 TREX1 TRIM21 STAT4
2 immune system MP:0005387 10.17 TROVE2 TLR5 TNFSF4 TREX1 TRIM21 STAT4
3 homeostasis/metabolism MP:0005376 10.15 TRIM21 STAT4 TLR5 TNFSF4 TREX1 FCGR2B
4 cardiovascular system MP:0005385 10.11 TLR5 TNFSF4 TREX1 ENG FCGR2B C4B
5 digestive/alimentary MP:0005381 9.98 TLR5 TREX1 ENG FCGR2B C4B CTLA4
6 mortality/aging MP:0010768 9.97 STAT4 TROVE2 TLR5 TREX1 SSB TRIM21
7 liver/biliary system MP:0005370 9.8 TLR5 TREX1 FCGR2B C4B PDCD1 CTLA4
8 renal/urinary system MP:0005367 9.61 STAT4 TROVE2 TREX1 TRIM21 FCGR2B C1QA
9 respiratory system MP:0005388 9.17 TLR5 TREX1 FCGR2B PDCD1 CTLA4 PTPN22

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 381)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 124-94-7 31307
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
11
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
12
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
14
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
15
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
16
Bortezomib Approved, Investigational Phase 4,Phase 2 179324-69-7 387447 93860
17
Sulfamethoxazole Approved Phase 4 723-46-6 5329
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Metformin Approved Phase 4 657-24-9 4091 14219
20
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
21
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
22 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
23
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
25
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
26
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
28 triamcinolone acetonide Phase 4,Phase 2,Phase 1
29 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
30 Atorvastatin Calcium Phase 4,Phase 2,Phase 3,Phase 1 134523-03-8
31 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2
32 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
33 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1
34 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
35 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
36 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
37 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
38 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
41 Triamcinolone diacetate Phase 4,Phase 2,Phase 1
42 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
44 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1
45 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
46 Vasoconstrictor Agents Phase 4,Phase 2
47 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
48 Hormones Phase 4,Phase 3,Phase 2,Phase 1
49 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 656)

# Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
5 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
6 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
7 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
8 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
9 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
10 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
11 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
12 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
13 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
14 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
15 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
16 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
17 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
18 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
19 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
20 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
21 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
22 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
23 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
24 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
25 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
26 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
27 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4 RAYOS;Prednisone
28 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
29 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
30 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
31 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
32 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
33 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
34 The Effect of Metformin on Reducing Lupus Flares Active, not recruiting NCT02741960 Phase 4 metformin;placebo
35 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
36 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
37 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
38 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Not yet recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
39 Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis Not yet recruiting NCT03214731 Phase 4 Artesunate
40 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
41 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
42 A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients Terminated NCT01316133 Phase 4 tacrolimus
43 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
44 Doxycycline Outcomes in Lupus Erythematosus Withdrawn NCT01014260 Phase 4 Placebo;Doxycycline
45 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
46 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
47 Velcade for Proliferative Lupus Nephritis Withdrawn NCT01169857 Phase 4 Velcade
48 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
49 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
50 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

MalaCards organs/tissues related to Lupus Erythematosus:

38
T Cells, Skin, B Cells, Heart, Endothelial, Eye, Kidney

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 6993)
# Title Authors Year
1
The interplay between tuberculosis and systemic lupus erythematosus. ( 29438163 )
2018
2
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
3
Clinical Factors Associated with Brain Volume Reduction in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations. ( 29449817 )
2018
4
Synchronous presentation of systemic lupus erythematosus and oral reticular lichen planus. ( 29387764 )
2018
5
Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. ( 29423919 )
2018
6
Anti-tubulin-I+-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations. ( 29427009 )
2018
7
Prevalence and factors associated with fatigue in female patients with systemic lupus erythematosus. ( 29439873 )
2018
8
DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. ( 29437559 )
2018
9
Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? ( 29119304 )
2018
10
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. ( 29061479 )
2018
11
Herpes zoster infection after topical steroid use in the setting of tumid lupus erythematosus. ( 29379863 )
2018
12
CCR6<sup>+</sup>Th cell distribution differentiates systemic lupus erythematosus patients based on anti-dsDNA antibody status. ( 29441231 )
2018
13
Subacute cutaneous lupus erythematosus presenting in twins. ( 29436018 )
2018
14
Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud's arthropathy. ( 29338586 )
2018
15
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
16
Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( 29451069 )
2018
17
Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy. ( 29449503 )
2018
18
Combination of ofatumumab and fresh frozen plasma in hypocomplementemic systemic lupus erythematosus: a case report. ( 29439647 )
2018
19
Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. ( 29294596 )
2018
20
Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). ( 29444908 )
2018
21
Pregnancy complicated by systemic lupus erythematosus and its outcome over 10 years. ( 29433371 )
2018
22
Latent systemic lupus erythematosus presenting with hypokalaemic quadriparesis and central pontine myelinolysis. ( 29429118 )
2018
23
Association of interleukin-10 gene single nucleotide polymorphisms with susceptibility to systemic lupus erythematosus in a Chinese population. ( 29199038 )
2018
24
An interesting case of systemic lupus erythematosus in a patient with Moebius syndrome. ( 29356035 )
2018
25
DNA induction of MDM2 promotes proliferation of human renal mesangial cells and alters peripheral B cells subsets in pediatric systemic lupus erythematosus. ( 29324237 )
2018
26
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
27
Olfactory function in systemic lupus erythematosus and systemic sclerosis. A longitudinal study and review of the literature. ( 29444467 )
2018
28
Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus. ( 29434811 )
2018
29
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. ( 29349515 )
2018
30
Systemic lupus erythematosus with C1q deficiency: treatment with fresh frozen plasma. ( 29113537 )
2018
31
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
32
Features, Treatment and Outcomes of Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus. ( 29342508 )
2018
33
Cardiac tamponade in systemic lupus erythematosus. ( 29048543 )
2018
34
Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. ( 29336019 )
2018
35
<i>Candida albicans</i> Pyomyositis in a Patient with Systemic Lupus Erythematosus. ( 29419450 )
2018
36
Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. ( 29431056 )
2018
37
Correction:<i>Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016</i>. ( 29440018 )
2018
38
Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus. ( 29451066 )
2018
39
The influence of functional polymorphic positions of HLA-DRI^1 molecules on risk for South Indian systemic lupus erythematosus patients. ( 29439646 )
2018
40
Multiple primary squamous cell carcinomas of the lower lip and tongue arising in discoid lupus erythematosus: a case report. ( 28967499 )
2018
41
Incidental Focal Acantholytic Dyskeratosis in a Patient with Discoid Lupus Erythematosus: A Possible Role for SPCA1 in the Pathogenesis of the Disease. ( 28966534 )
2017
42
Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus. ( 28237708 )
2017
43
Association Between TNF-I+ Promoter -308 A/G Polymorphism and Systemic Lupus Erythematosus Susceptibility: A Case-Control Study and Meta-Analysis. ( 27943420 )
2017
44
Discoid Lupus Erythematosus Complicated with Pregnancy-induced Hemophagocytic Syndrome. ( 28626188 )
2017
45
Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. ( 28618892 )
2017
46
Association Between Major Histocompatibility Complex Class I Chain-Related Gene Polymorphisms and Susceptibility of Systemic Lupus Erythematosus. ( 29078849 )
2017
47
Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity. ( 29080553 )
2017
48
Gestational gigantomastia in systemic lupus erythematosus. ( 29272260 )
2017
49
TIGIT signalling pathway negatively regulates CD4(+) T-cell responses in systemic lupus erythematosus. ( 28108989 )
2017
50
Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study. ( 28091805 )
2017

Variations for Lupus Erythematosus

ClinVar genetic disease variations for Lupus Erythematosus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395
2 ENG NM_000118.3(ENG): c.816+6T> C single nucleotide variant Pathogenic rs759191907 GRCh38 Chromosome 9, 127825225: 127825225

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 C1QA C1QB C1QC C4A C4B CTLA4
2
Show member pathways
13.58 C1QA C1QB C1QC C4A C4B SNRPB
3 12.39 CTLA4 PDCD1 PTPN22 STAT4 TNFSF4
4
Show member pathways
12.29 C1QA C1QB C1QC TLR5
5
Show member pathways
11.93 C1QA C1QB C1QC C4A C4B
6 11.86 C1QA C1QB C1QC C4A C4B
7
Show member pathways
11.78 C1QA C1QB C1QC C4A C4B
8
Show member pathways
11.57 C1QA C1QB C1QC C4A C4B
9 11.52 CTLA4 FCGR2B PDCD1 TLR5
10 11.23 C1QA C1QB C1QC C4A C4B
11 11.18 C1QA C1QB C1QC
12 10.85 C1QA C1QB C1QC C4A C4B FCGR2B

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular ribonucleoprotein complex GO:0030529 9.62 SNRPB SSB TRIM21 TROVE2
2 external side of plasma membrane GO:0009897 9.46 CTLA4 ENG FCGR2B PDCD1
3 collagen trimer GO:0005581 9.43 C1QA C1QB C1QC
4 blood microparticle GO:0072562 9.26 C1QB C1QC C4A C4B
5 complement component C1 complex GO:0005602 8.62 C1QA C1QB

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.89 C4A C4B CTLA4 PTPN22 TLR5
2 innate immune response GO:0045087 9.8 C1QA C1QB C1QC C4A C4B TLR5
3 regulation of type I interferon production GO:0032479 9.55 TREX1 TRIM21
4 complement activation, classical pathway GO:0006958 9.55 C1QA C1QB C1QC C4A C4B
5 negative regulation of B cell proliferation GO:0030889 9.54 CTLA4 FCGR2B
6 regulation of innate immune response GO:0045088 9.52 FCGR2B PTPN22
7 negative regulation of immune response GO:0050777 9.51 CTLA4 FCGR2B
8 histone mRNA metabolic process GO:0008334 9.48 SNRPB SSB
9 negative regulation of B cell activation GO:0050869 9.46 BANK1 FCGR2B
10 negative regulation of interleukin-6 secretion GO:1900165 9.43 BANK1 PTPN22
11 regulation of adaptive immune response GO:0002819 9.4 FCGR2B TNFSF4
12 positive regulation of apoptotic cell clearance GO:2000427 9.37 C4A C4B
13 regulation of complement activation GO:0030449 9.35 C1QA C1QB C1QC C4A C4B
14 negative regulation of regulatory T cell differentiation GO:0045590 9.32 CTLA4 TNFSF4
15 complement activation GO:0006956 9.02 C1QA C1QB C1QC C4A C4B

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase binding GO:1990782 9.16 BANK1 PTPN22
2 serine-type endopeptidase activity GO:0004252 9.02 C1QA C1QB C1QC C4A C4B
3 U2 snRNA binding GO:0030620 8.96 SNRPB TROVE2

Sources for Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....